|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15621563156415651566156715681569157015711572...15771578» |
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
New P2 trial, Metastases: A Study of XL184 (Cabozantinib) in Endometrial Cancer (clinicaltrials.gov) - Mar 18, 2013
P2, N=36, Not yet recruiting, Sponsor: University Health Network, Toronto
- | Oncophage (Heat Shock Protein Peptide Complex-96) / Agenus, Avastin (bevacizumab) / Roche
New P2 trial, Surgery: Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery (clinicaltrials.gov) - Mar 18, 2013
P2, N=222, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
- | Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
New P2 trial, Combination therapy, Metastases: Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab (clinicaltrials.gov) - Mar 18, 2013
P2, N=35, Recruiting, Sponsor: Christina Wu
- bafetinib (INNO-406) / LadRx
Enrollment change: Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=7, Completed, Sponsor: City of Hope Medical Center
N=18 --> 7
- RG4733 / Roche
Enrollment closed, Combination therapy: RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Mar 17, 2013
P1, N=24, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=18 --> 7 Recruiting --> Active, not recruiting
- bafetinib (INNO-406) / LadRx
Trial completion: Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=7, Completed, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion, Surgery, Metastases: Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 17, 2013
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- melphalan / Generic mfg., busulfan / Generic mfg., thiotepa / Generic mfg.
Enrollment change: Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors (clinicaltrials.gov) - Mar 14, 2013
P2, N=10, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed N=30 --> 10
- sorafenib / Generic mfg.
Enrollment closed, Metastases: Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer (clinicaltrials.gov) - Mar 14, 2013
P2, N=74, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=30 --> 10 Recruiting --> Active, not recruiting
- Endostar (recombinant human endostatin) / Simcere
New P2 trial: Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 13, 2013
P2, N=30, Recruiting, Sponsor: Peng Yuan
- |||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment open, Metastases: A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas (clinicaltrials.gov) - Mar 13, 2013
P2, N=54, Recruiting, Sponsor: Northwestern University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- cyclophosphamide / Generic mfg.
Enrollment open, Surgery, Metastases: Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 12, 2013
P1, N=7, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Suspended --> Recruiting
- Mepact (mifamurtide) / Takeda
Trial initiation date: Surveillance Study of Patients With Newly Diagnosed Osteosarcoma (clinicaltrials.gov) - Mar 11, 2013
P=N/A, N=25, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Suspended --> Recruiting Initiation date: Oct 2010 --> Dec 2011
- Clinical data, Trial initiation date: CH01: Proton Therapy for Chordomas and/or Chondrosarcomas (clinicaltrials.gov) - Mar 10, 2013
P=N/A, N=300, Recruiting, Sponsor: University of Florida
Initiation date: Oct 2010 --> Dec 2011 Initiation date: Oct 2006 --> Jan 2007
- Recentin (cediranib) / AstraZeneca
Enrollment change, Combination therapy: Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Mar 10, 2013
P1/2, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Oct 2006 --> Jan 2007 N=80 --> 40
- Avastin (bevacizumab) / Roche, RG4733 / Roche
Enrollment closed: RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma (clinicaltrials.gov) - Mar 10, 2013
P1/2, N=13, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=80 --> 40 Recruiting --> Active, not recruiting
- cixutumumab (IMC A12) / Eli Lilly
Enrollment closed, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 10, 2013
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Votrient (pazopanib) / Novartis, BeiGene
Enrollment open, Metastases: Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial (clinicaltrials.gov) - Mar 7, 2013
P2, N=74, Recruiting, Sponsor: Grupo Espanol de Investigacion en Sarcomas
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||||| Votrient (pazopanib) / Novartis, BeiGene
Trial completion: PALETTE: Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy (clinicaltrials.gov) - Mar 7, 2013
P3, N=369, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- New P2 trial: Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors (clinicaltrials.gov) - Mar 6, 2013
P2, N=12, Not yet recruiting, Sponsor: Samsung Medical Center
- pomalidomide / Generic mfg.
Metastases: Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 5, 2013
P2, N=7, Terminated, Sponsor: Celgene Corporation
Active, not recruiting --> Completed Completed --> Terminated; Study enrollment was terminated due to a corporate strategic decision unrelated to patient safety.
- pomalidomide / Generic mfg.
Metastases: Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 5, 2013
P2, N=7, Terminated, Sponsor: Celgene Corporation
Completed --> Terminated; Study enrollment was terminated due to a corporate strategic decision unrelated to patient safety. Initiation date: May 2008 --> Aug 2008
- | Biomarker, New P1/2 trial: 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy (clinicaltrials.gov) - Mar 5, 2013
P1/2, N=100, Recruiting, Sponsor: Stanford University
- Enrollment closed: A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas (clinicaltrials.gov) - Mar 5, 2013
P=N/A, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Initiation date: May 2008 --> Aug 2008 Recruiting --> Active, not recruiting
- everolimus / Generic mfg., sorafenib / Generic mfg.
New P2 trial: SERIO: Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma (clinicaltrials.gov) - Mar 3, 2013
P2, N=37, Active, not recruiting, Sponsor: Italian Sarcoma Group
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Enrollment open, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Mar 3, 2013
P1b, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- perifosine (D21266) / AEterna Zentaris, Torisel (temsirolimus) / Pfizer
Enrollment closed: Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma (clinicaltrials.gov) - Mar 3, 2013
P1/2, N=92, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Cilcane (cilengitide) / Iceni Pharma
Trial termination: EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma (clinicaltrials.gov) - Feb 28, 2013
P1, N=30, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Completed --> Terminated; Administratively complete.
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
New P1 trial, Myeloid-derived suppressor cells: Dendritic Cell Vaccine for Children and Adults With Sarcoma (clinicaltrials.gov) - Feb 28, 2013
P1, N=56, Recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
- Preclinical, Enrollment change, FDG PET: Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer (clinicaltrials.gov) - Feb 27, 2013
P=N/A, N=8, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Completed --> Terminated; Administratively complete. N=20 --> 8
- Trial completion, Preclinical, FDG PET: Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer (clinicaltrials.gov) - Feb 27, 2013
P=N/A, N=8, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=20 --> 8 Recruiting --> Completed
- Enrollment open, Biopsy: Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=128, Recruiting, Sponsor: Northwestern University
Recruiting --> Completed Active, not recruiting --> Recruiting
- erlotinib / Generic mfg., isotretinoin / Generic mfg.
Enrollment change: Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma (clinicaltrials.gov) - Feb 26, 2013
P1, N=5, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Recruiting N=30 --> 5
- topotecan / Generic mfg., melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment closed, Metastases: Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=25, Active, not recruiting, Sponsor: City of Hope Medical Center
N=30 --> 5 Recruiting --> Active, not recruiting
- Farydak (panobinostat) / Secura Bio
Trial completion, Metastases: ESTIM-LBH: Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure (clinicaltrials.gov) - Feb 26, 2013
P2, N=53, Completed, Sponsor: Centre Leon Berard
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: Proton Beam Radiation Therapy in Treating Patients With Retroperitoneal Sarcoma (clinicaltrials.gov) - Feb 24, 2013
P1, N=54, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Biomarker, Enrollment open: Permission to Collect Blood Over Time for Research (clinicaltrials.gov) - Feb 24, 2013
P=N/A, N=345, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Completed Withdrawn --> Recruiting
- ||| imatinib / Generic mfg.
Trial initiation date, Stroma: Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) (clinicaltrials.gov) - Feb 21, 2013
P4, N=150, Recruiting, Sponsor: Novartis Pharmaceuticals
Withdrawn --> Recruiting Initiation date: May 2008 --> Aug 2008
- | Avastin (bevacizumab) / Roche
Enrollment change: Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma (clinicaltrials.gov) - Feb 21, 2013
P2, N=29, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Initiation date: May 2008 --> Aug 2008 N=10 --> 29
- sirolimus / Generic mfg., erlotinib / Generic mfg.
Enrollment change: Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme (clinicaltrials.gov) - Feb 21, 2013
P2, N=32, Completed, Sponsor: Duke University
N=10 --> 29 N=20 --> 32
- |||| imatinib / Generic mfg.
Enrollment open, Stroma: Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) (clinicaltrials.gov) - Feb 21, 2013
P4, N=150, Recruiting, Sponsor: Novartis Pharmaceuticals
N=20 --> 32 Active, not recruiting --> Recruiting
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial completion: Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma (clinicaltrials.gov) - Feb 20, 2013
P2, N=14, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- Yervoy (ipilimumab) / BMS
Enrollment open, Metastases: Ipilimumab and Imatinib Mesylate in Advanced Cancer (clinicaltrials.gov) - Feb 19, 2013
P1, N=96, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Enrollment change, Metastases: Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy (clinicaltrials.gov) - Feb 18, 2013
P3, N=200, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting N=100 --> 200
- | Caprelsa (vandetanib) / Sanofi
Trial completion, Combination therapy: Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas (clinicaltrials.gov) - Feb 18, 2013
P1, N=49, Completed, Sponsor: Annick Desjardins
N=100 --> 200 Active, not recruiting --> Completed
- ||| imatinib / Generic mfg., hydroxyurea / Generic mfg., everolimus / Generic mfg.
Trial completion, Combination therapy: Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG (clinicaltrials.gov) - Feb 18, 2013
P1, N=78, Completed, Sponsor: Annick Desjardins
Active, not recruiting --> Completed Active, not recruiting --> Completed
- celecoxib oral / Generic mfg.
Enrollment change, Surgery: Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery (clinicaltrials.gov) - Feb 17, 2013
P1, N=3, Completed, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Active, not recruiting --> Completed N=24 --> 3
- | conatumumab (AMG 655) / Amgen
Enrollment change: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Feb 13, 2013
P2, N=12, Recruiting, Sponsor: Amgen
N=24 --> 3 N=30 --> 12
- Clinical: CoRDS: Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (clinicaltrials.gov) - Feb 13, 2013
P=N/A, N=10000, Recruiting, Sponsor: Sanford Health
- | conatumumab (AMG 655) / Amgen
Enrollment open: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Feb 13, 2013
P2, N=12, Recruiting, Sponsor: Amgen
N=30 --> 12 Active, not recruiting --> Recruiting